Physiologically active hydrogel (in situ gel) of sparfloxacin and its evaluation for ocular retention using gamma scintigraphy

被引:20
作者
Gupta, Himanshu [1 ,2 ]
Malik, Aqil [1 ]
Khar, R. K. [1 ]
Ali, Asgar [1 ]
Bhatnagar, Aseem [2 ]
Mittal, Gaurav [2 ]
机构
[1] Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi, India
[2] Minist Def, Inst Nucl Med & Allied Sci, Dept Nucl Med, New Delhi, India
关键词
Gamma scintigraphy; in situ gel; ocular delivery; sparfloxacin;
D O I
10.4103/0975-7406.160015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Due to the structure and physiological barrier of eye, only 1% of instilled dose is available for action on the corneal surface. In this work, we developed and evaluated chitosan (pH sensitive) and gellan gum (ion sensitive) in situ gel of sparfloxacin to improve precorneal residence time. Materials and Methods: A protocol for radiolabeling of sparfloxacin with Tc-99m was optimized to study the ocular retention using gamma scintigraphy technique. Results: The clear formulation was developed. In vitro release showed a sustained and prolonged release compared to plain eye drop solution. Dynamic and static gamma scintigraphy showed better retention than plain eye drops. The ocular tolerance test (hen's egg test-chorioallantoic membrane test and infra-red study) showed that the formulation is nonirritant and can be used as ocular vehicle. Conclusion: Radiolabel protocol for sparfloxacin was successfully developed and evaluated on ocular retention studies of developed in situ gel. The developed in situ gel is non irritant and can go further with clinical evaluation.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 14 条
[1]  
[Anonymous], 1990, BIOADHESIVE DRUG DEL
[2]  
Chiou GC, 1986, METHODS DRUG DELIVER, P203
[3]  
DAVIS SS, 1992, EUR J NUCL MED, V19, P971
[4]  
Felt O., 1999, ENCY CONTROLLED DRUG, V2, P605
[5]   Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system [J].
Gupta, Himanshu ;
Jain, Sanyog ;
Mathur, Rashi ;
Mishra, Pushpa ;
Mishra, Anil K. ;
Velpandian, T. .
DRUG DELIVERY, 2007, 14 (08) :507-515
[6]   Carbopol/pluronic phase change solutions for ophthalmic drug delivery [J].
Lin, HR ;
Sung, KC .
JOURNAL OF CONTROLLED RELEASE, 2000, 69 (03) :379-388
[7]  
Maurice DM, 1987, OPHTHALMIC DRUG DELI, V11, P19
[8]  
Ranade V.V., 1996, DRUG DELIVERY SYSTEM, P209
[9]   OCULAR DRUG DELIVERY - PHARMACOKINETIC CONSIDERATIONS [J].
SCHOENWALD, RD .
CLINICAL PHARMACOKINETICS, 1990, 18 (04) :255-269
[10]  
Singh AK, 2004, INDIAN J PHARM SCI, V66, P18